Otsuka Pharmaceutical Factory has reached an agreement with Mitsui & Co to acquire a remaining 20% interest in Otsuka Pharmaceutical India Private from the Mitsui.

The acquisition will make Otsuka Pharmaceutical India Private a wholly-owned subsidiary of Otsuka Pharmaceutical Factory.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

In 2013, Otsuka Pharmaceutical Factory established Otsuka Pharmaceutical India Private as part of a joint venture (JV) with Claris Lifesciences (owning a 20% stake) and Mitsui (20%). The final 20% was owned by Claris, which was acquired by

“Shin Kowa Pharmaceutical has acquired Hakushindo Pharmaceutical.”

Otsuka Pharmaceutical Factory acquired a 20% stake held by Claris in September 2017.

Mitsui is a diversified trading company based in Japan. Otsuka Pharmaceutical India Private provides intravenous and clinical nutrition products.

Shin Kowa Pharmaceutical has acquired Hakushindo Pharmaceutical.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Shin Kowa Pharmaceutical produces NMN (ß nicotinamide mononucleotide). The firm expects the acquisition to enable it to build up the clinical trial results database of the Hiroshima University Graduate School of Biomedical & Health Sciences Project Research Center.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact